ALX Oncology has dosed the first patient in its Phase II investigator-sponsored clinical trial of evorpacept for the treatment of platinum-resistant ovarian cancer.
A next generation CD47 blocker, evorpacept is evaluated in combination with liposomal doxorubicin along with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab).
Go deeper with GlobalData
The open-label, single-arm study was initiated at the UPMC Hillman Cancer Center in the US.
It is led by Dr Haider Mahdi of the UPMC Magee-Womens Research Institute .
He also works at the University of Pittsburgh as an assistant professor of Obstetrics, Gynecology and Reproductive Sciences department.
See Also:
Mahdi said: “Ovarian cancer patients who develop platinum-resistant disease have poor prognosis, and are in desperate need for new treatment options that are safe and effective.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“From a mechanistic standpoint, CD47 blockade has been shown to complement chemotherapeutic agents and immune checkpoint inhibitors.
“We anticipate that the combination of evorpacept, liposomal doxorubicin and pembrolizumab may lead to improved efficacy and a more favourable benefit-risk profile.”
ALX Oncology has gained global marketing rights for evorpacept and intends to expand its treatment in multiple solid tumour indications and haematologic malignancies.
Last month, ALX Oncology signed a clinical trial partnership with Sanofi to investigate the safety, efficacy, pharmacokinetics and biomarker data of evorpacept plus SARCLISA and dexamethasone.
